Certara, Inc. (CERT)

Market Cap	1.24B -34.8%
Revenue (ttm)	415.55M +11.5%
Net Income	10.88M
EPS	0.07
Shares Out	159.27M
PE Ratio	114.87
Forward PE	15.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,658,434
Open	8.32
Previous Close	8.30
Day's Range	7.49 - 8.45
52-Week Range	7.49 - 15.69
Beta	1.46
Analysts	Buy
Price Target	12.78 (+64.8%)
Earnings Date	Feb 26, 2026

About CERT

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and tr...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 1,546
• Stock Exchange: NASDAQ
• Ticker Symbol: CERT
• Website: https://www.certara.com

Financial Performance

In 2024, Certara's revenue was $385.15 million, an increase of 8.70% compared to the previous year's $354.34 million. Losses were -$12.05 million, -78.23% less than in 2023.

Analyst Summary

According to 10 analysts, the average rating for CERT stock is "Buy." The 12-month stock price target is $12.78, which is an increase of 64.80% from the latest price.

Price Target

$12.78

(64.80% upside)

Analyst Consensus: Buy